Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERTEX PHARMACEUTICALS INC / MA Director's Dealing 2021

Feb 5, 2021

29864_dirs_2021-02-05_0b070e4e-7462-4120-b65a-797728d3ce36.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-03

Reporting Person: LEIDEN JEFFREY M (Director, Executive Chairman)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-03 Common Stock A 31498 $0.00 Acquired 33809 Direct
2021-02-03 Common Stock A 31462 $0.00 Acquired 65271 Direct
2021-02-03 Common Stock A 20928 $0.00 Acquired 86199 Direct
2021-02-03 Common Stock F 8599 $215.03 Disposed 77600 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 440 Indirect

Footnotes

F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.

F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/10/2021.

F3: Restricted stock unit award that fully vested upon grant.